Humanization of an anti-CD34 monoclonal antibody by complementarity- determining region grafting based on computer-assisted molecular modelling

Journal of Biochemistry

Volumn 144, Issue 1, 2008, Pages 115-120

  Hou, Sheng ^a,b   Li, Bohua ^a,b   Wang, Ling ^a   Qian, Weizhu ^a,b   Zhang, Dapeng ^a   Hong, Xueyu ^a   Wang, Hao ^a,b   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Center for Cell Engineering and Antibody   (China)

Author keywords

CD34; Hematopoietic stem cells; Humanization; Immunogenicity; Monoclonal antibody

Indexed keywords

CD34 ANTIBODY; MONOCLONAL ANTIBODY 4C8; MONOCLONAL ANTIBODY CD34;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPLEMENTARITY DETERMINING REGION; COMPUTER MODEL; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOLECULAR MODEL; NONHUMAN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BINDING, COMPETITIVE; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; IMAGING, THREE-DIMENSIONAL; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

MURINAE;

EID: 46849108508     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvn052     Document Type: Article

References (32)

1. Bhattacharya, A., Slatter, M.A., Chapman, C.E., Barge, D., Jackson, A., Flood, T.J., Abinun, M., Cant, A.J., and Gennery, A.R. (2005) Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant. 36, 295-299
2. Peters, C. and Steward, C.G. (2003) Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 31, 229-239
3. Gratwohl, A., Baldomero, H., Passweg, J., Frassoni, F., Niederwieser, D., Schmitz, N., and Urbano-Ispizua, A. (2003) Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 17, 941-959
4. Civin, C.I., Strauss, L.C., Brovall, C., Fackler, M.J., Schwartz, J.F., and Shaper, J.H. (1984) Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol. 133, 157-165
5. Krause, D.S., Fackler, M.J., Civin, C.I., and May, W.S. (1996) CD34: structure, biology, and clinical utility. Blood 87, 1-13
6. He, X.Y., Antao, V.P., Basila, D., Marx, J.C., and Davis, B.R. (1992) Isolation and molecular characterization of the human CD34 gene. Blood 79, 2296-2302
7. Sutherland, D.R., Marsh, J.C., Davidson, J., Baker, M.A., Keating, A., and Mellors, A. (1992) Differential sensitivity of CD34 epitopes to cleavage by Pasteurella haemolytica glycoprotease: implications for purification of CD34-positive progenitor cells. Exp. Hematol. 20, 590-599
8. Steen, R., Tjønnfjord, G.E., Gaudernack, G., Brinch, L., and Egeland, T. (1996) Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells. Br. J. Haematol. 94, 597-605
9. Otto, M., Chen, X., Martin, W.J., Leung, W., Knowles, J., Holladay, M., Houston, J., Handgretinger, R., and Barfield, R.C. (2007) Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells 25, 537-542
10. Morrison, S.L., Johnson, M.J., Herzenberg, L.A., and Oi, V.T. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl Acad. Sci. USA. 81, 6851-6855
11. Boulianne, G.L., Hozumi, N., and Shulman, M.J. (1984) Production of functional chimaeric mouse/human antibody. Nature 312, 643-646
12. LoBuglio, A.F., Wheeler, R.H., Trang, J., Haynes, A., Rogers, K., Harvey, E.B., Sun, L., Ghrayeb, J., and Khazaeli, M.B. (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl Acad. Sci. USA. 86, 4220-4224
13. Jaffers, G.J., Fuller, T.C., Cosimi, A.B., Russell, P.S., Winn, H.J., and Colvin, R.B. (1986) Monoclonal antibody therapy. Anti-idiotypic and non-antiidiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41, 572-528
14. Hesse, C.J., Heyse, P., Stolk, B.J., Balk, A.H., Jutte, N.H., Mochtar, B., and Weimar, W. (1990) The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients. Transplant. Proc. 22, 1772-1773
15. Norman, D.J. (1995) Mechanisms of action and overview of OKT3. Ther. Drug. Monit. 17, 615-620
16. Tsurushita, N., Hinton, P.R., and Kumar, S. (2005) Design of humanized antibodies: from anti-Tac to Zenapax. Methods 36, 69-83
17. Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., and Winter, G. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525
18. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332, 323-327
19. Qian, W., Wang, L., Li, B., Wang, H., Hou, S., Hong, X., Zhang, D., and Guo, Y. (2008) Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Biochem. Biophys. Res. Commun. 367, 497-502
20. Li, B., Wang, H., Dai, J., Ji, J., Qian, W., Zhang, D., Hou, S., and Guo, Y. (2005) Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116, 487-498
21. Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S., and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th edn, United States Department of Health and Human Services, Bethesda, MD.
22. Queen, C., Schneider, W.P., Selick, H.E., Payne, P.W., Landolfi, N.F., Duncan, J.F., Avdalovic, N.M., Levitt, M., Junghans, R.P., and Waldmann, T.A (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl Acad. Sci. USA. 86, 10029-10033
23. Pulito, V.L., Roberts, V.A., Adair, J.R., Rothermel, A.L., Collins, A.M., Varga, S.S., Martocello, C., Bodmer, M., Jolliffe, L.K., and Zivin, R.A. (1996) Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J. Immunol. 156, 2840-2850
24. Nakamura, K., Tanaka, Y., Shitara, K., and Hanai, N. (2001) Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer. Immunol. Immunother. 50, 275-284
25. Kostelny, S.A., Link, B.K., Tso, J.Y., Vasquez, M., Jorgensen, B.H., Wang, H., Hall, W.C., and Weiner, G.J. (2001) Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. J. Cancer 93, 556-565
26. Kettleborough, C.A., Saldanha, J., Heath, V.J., Morrison, C.J., and Bendig, M.M. (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4, 773-783
27. Wu, H., Nie, Y., Huse, W.D., and Watkins, J.D. (1999) Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294, 151-162
28. Kipriyanov, S.M. and Le Gall, F. (2004) Generation and production of engineered antibodies. Mol. Biotechnol. 26, 39-60
29. Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong, W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA. 89, 4285-4289
30. Graves, S.S., Goshorn, S.C., Stone, D.M., Axworthy, D.B., Reno, J.M., Bottino, B., Searle, S., Henry, A., Pedersen, J., Rees, A.R., and Libby, R.T. (1999) Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. Clin. Cancer Res. 5, 899-908
31. Li, B., Wang, H., Zhang, D., Qian, W., Hou, S., Shi, S., Zhao, L., Kou, G., Cao, Z., Dai, J., and Guo, Y. (2007) Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. Biochem. Biophys. Res. Commun. 357, 951-956
32. Leung, S.O., Goldenberg, D.M., Dion, A.S., Pellegrini, M.C., Shevitz, J., Shih, L.B., and Hansen, H.J. (1995) Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol. Immunol. 32, 1413-1427